Motif strikes a deal needed to trigger Nasdaq IPO; OncoGenex cuts more staffers to conserve cash

UK antibiotic developer Motif Bio (AIM: MTFB) may have sorted out its financial woes, for now. The biotech made a deal to float its US IPO, conditional on a European placement to raise $25 million. And the company says it has the support needed to get that done.

OncoGenex Pharmaceuticals is laying off another 5 staffers, according to an SEC filing. The Bothell, WA-based company cut 27% of its staff back in February as it looked to conserve enough cash to see through a Phase III program.

New York-based Neurotrope, a penny stock biotech which trades OTC, has raised $20 million to fund its research on new drugs for neurodegeneration, including Alzheimer’s. The biotech says it plans to spend the cash on its Phase II study.

The best place to read Endpoints News? In your inbox.

Comprehensive daily news report for those who discover, develop, and market drugs. Join 44,800+ biopharma pros who read Endpoints News by email every day.

Free Subscription

Sr. Manager, Regulatory Affairs, CMC
CytomX Therapeutics San Francisco, CA
Marketing Associate - Demand Generation
Catalytic Data Science Charleston, SC
Associate Principal, Life Sciences Partnerships
Flatiron Health New York City or San Francisco

Visit Endpoints Careers ->